HopeStage
Back to all studies
CompletedNCT04932291

Vafidemstat for Borderline Personality Disorder

This study is completed in the United States, in Bulgaria, in Germany, .... It is testing vafidemstat for Borderline Personality Disorder.

Personality disorders, Borderline personalityDrugFrom 18 Years to 65 Years

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Then choose your country and confirm availability with each study site.

In plain English

Key information made simple

What is this study testing?

This study is testing whether Vafidemstat may be useful for adults experiencing personality disorders.

What would participation involve?

Participants may receive Vafidemstat, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in Bulgaria, in Germany, and in Serbia.

Who is it mainly for?

This study appears to be mainly for adults with personality disorders.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.

Your next step

Check the study details

Check the official source, then confirm these points with the research team.

View official study record (opens in a new tab)
  • Recruitment and eligibility

    Is a site open, and who can take part?

  • Visits and time

    Where are visits, can any be remote, and how much time is needed?

  • Costs and support

    What costs, reimbursement or compensation apply?

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateStarted: March 26, 2021
Recruitment status
Completed
Enrollment listed in the registry
211
Sponsor
Oryzon Genomics S.A.
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States, Bulgaria, Germany, ...
Age range
From 18 Years to 65 Years
Official registry ID
NCT04932291
Official title
"A Double-blind, Randomized, Placebo-controlled, Adaptive 14-week Phase IIb Trial to Evaluate the Efficacy and Safety of Vafidemstat in an Adult Borderline Personality Disorder (BPD) Population (PORTICO)"

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Loading the security check...
Study ID: NCT04932291. We help you review the study, but cannot decide medical eligibility.

Recruitment & locations

Completed

Oceanside, United States · Hialeah, United States · Miami, United States

15 more locations
  • Chicago, United States
  • Elgin, United States
  • Watertown, United States
  • Cherry Hill, United States
  • Cedarhurst, United States
  • New York, United States
  • Everett, United States
  • Sofia, Bulgaria
  • Varna, Bulgaria
  • München, Germany
  • Berlin, Germany
  • Belgrade, Serbia
  • Kragujevac, Serbia
  • Barcelona, Spain
  • Madrid, Spain
Registry details
Registry conditions (original wording)

Borderline Personality Disorder

FAQ

Questions about this study

Who is behind this study?

The study sponsor is Oryzon Genomics S.A.

Does this study involve medication?

Yes. The study involves medication, including vafidemstat and Placebo.

Who can participate?

Listed age limits: 18 years to 65 years.

Is this study still recruiting?

The registry lists this study as completed.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me